Cour Pharmaceuticals Development Co., Inc.

We are headed to the Myasthenia Gravis Foundation of America, Inc.’s National Patient Conference in Phoenix from March 30 to April 1. Visit booth 211 to connect with our team and learn more about the Phase 1b/2a clinical trial evaluating our investigational treatment for #MyastheniaGravis. We look forward to meeting you there! #ClinicalResearch #MGCommunity

Next week, our Chief Medical Officer, Paul Peloso, M.D., will speak at the 7th Annual Treg-Directed Therapies Summit in Boston. During a panel and presentation, he will explore the applications of Treg modulation and how it is shaping the discovery and development of new therapies. Learn more here: https://bit.ly/4ip2fZU #AutoimmuneDiseases #TregTherapies

At COUR, we are advancing nanoparticles developed with our platform technology for antigen-specific immune tolerance. With our therapies, we aim to reprogram the immune system to treat #AutoimmuneDiseases without broad immunosuppression. Check out this article by Gail Dutton in Genetic Engineering & Biotechnology News to learn more about how we are working to address the root cause of diseases including #PrimaryBiliaryCholangitis (PBC), #Type1Diabetes (#T1D), and #MyastheniaGravis (MG): https://bit.ly/43kz1q7

At COUR, we are working to reprogram the immune system and restore lives with our next-generation, disease-modifying therapies. During #AutoimmuneDiseaseAwarenessMonth, we join the 23M+ people living with #AutoimmuneDiseases in the United States, as well as many more around the world, who are raising #AutoimmuneAwareness. #PrimaryBiliaryCholangitis #Type1Diabetes #T1D #MyastheniaGravis

We're #hiring a new Associate Scientist- Nanoparticle in Skokie, Illinois. Apply today or share this post with your network.

We're #hiring a new Senior Manager, Quality Systems in Skokie, Illinois. Apply today or share this post with your network.

We're #hiring a new Senior Operations Specialist in Skokie, Illinois. Apply today or share this post with your network.

We are officially #GPTWCertified. This recognition highlights our dedication to building a collaborative and supportive workplace where every voice matters. Huge thanks to our incredible team who works hard as we aim to transform the future of #AutoimmuneDisease treatment with our platform for antigen-specific immune tolerance. Learn more: https://bit.ly/4gR91WE #GreatPlaceToWork Great Place To Work US

Our CEO, Dannielle Appelhans, recently spoke with BioSpace's Annalee Armstrong about our clinical progress in #PrimaryBiliaryCholangitis, #Type1Diabetes, and #MyastheniaGravis.   Check out the article in the post below for details from their conversation. 

Later this month, members of our team will present at the 8th Antigen-Specific Immune Tolerance Summit in Boston from February 25-27. Our VP, Research, Adam Elhofy, PhD, will discuss our #nanoparticle in Phase 2 clinical development, which has the potential to be the first disease-modifying treatment for #PrimaryBiliaryCholangitis (#PBC). Our Director of Immunology, Joe Podojil, PhD, will present on our nanoparticle for #Type1Diabetes (#T1D), which will enter the clinic later this year. He will also participate in a panel covering the need for autoantigens versus tissue-specific antigens. As we continue to move forward next-generation disease-modifying therapies based on our platform for antigen-specific immune tolerance, we are eager to engage our peers in the field as we advance the future of treating #AutoimmuneDiseases. Find more information here: https://lnkd.in/dCb8FRkZ